ABSTRACT
OBJECTIVE: To compare the changes in serum sodium and acid/base status in patients receiving hypotonic and isotonic solutions. DESIGN: A randomised, controlled and double-blind clinical trial. SETTING: Department of Paediatrics in a tertiary general hospital (Hospital Universitario Austral) in Buenos Aires, Argentina. PATIENTS: Children between 29 days and 15 years of age who were hospitalised in the paediatric intensive care unit and general hospital between 12 January 2010 and 30 November 2016, and who required exclusively parenteral maintenance solutions for at least 24 hours. INTERVENTIONS: A hypotonic solution with 77 mEq/L sodium chloride (0.45% in 5% dextrose) and isotonic solution with 150 mEq/L (0.9% in 5% dextrose) were infused for 48 hours and were labelled. MAIN OUTCOME MEASURE: The main outcome was to evaluate the incidence of hyponatraemia between patients treated with parenteral hydration with hypotonic or isotonic fluids. The secondary outcome was to estimate the incidence of metabolic acidosis induced by each of the solutions. RESULTS: The 299 patients in the present study were randomised to groups that received the hypotonic solution (n=154) or isotonic solution (n=145). The mean serum sodium concentration measurements at 12 hours were 136.3±3.9 mEq/L and 140.1±2.3 mEq/L in the hypotonic and isotonic groups, respectively, with a hyponatraemia incidence of 8.27% (n=12) and 18.8% (n=29) (p<0.001). At 24 hours, 12.4% (n=18) of the isotonic group had developed hyponatraemia compared with 46.1% (n=71) of the hypotonic group (p<0.001). The mean serum sodium concentration measurements were 134.4±5.6 and 139.3±3.1, respectively. No patient developed hypernatraemia (serum sodium concentrations >150 mEq/L) or other adverse outcomes. The relative risk in the hypotonic group was 3.7 (95% CI 2.3 to 5.9), almost four times the risk of developing hyponatraemia than those who received isotonic fluids. There were also no significant differences between the groups with regard to the development of metabolic acidosis. Hypotonic solution, age <12 months and postoperative abdominal surgery were risk factors associated with hyponatraemia. CONCLUSIONS: The incidence of iatrogenic hyponatraemia was greater with the administration of hypotonic fluids compared with that of isotonic fluids. There were no significant differences in the incidence of metabolic acidosis between the groups.
ABSTRACT
INTRODUCTION: Magnesium sulfate is a calcium antagonist that inhibits bronchial smooth muscle contraction promoting bronchodilation. It is used for the management of acute severe asthma in children; however most of the studies have been performed in adults. OBJECTIVE: To evaluate the effectiveness of intravenous magnesium sulfate for the treatment of pediatric patients with acute severe asthma exacerbations. POPULATION AND METHODS: A clinical, randomized, controlled trial was conducted between March 2006 and March 2011 at Hospital Universitario Austral. Children with acute severe asthma admitted to the emergency department were randomized into two groups. Group A (control group): standard protocol for the initial treatment of acute asthma exacerbation. Group B: treatment protocol with magnesium sulphate for acute severe asthma exacerbation. The primary outcome was the requirement of invasive or non invasive mechanical ventilation support. RESULTS: One hundred and forty three patients randomized into 2 groups were analyzed. The treatment group included 76 patients receiving magnesium sulfate within the first hour of the initiation of rescue treatment at the hospital, and the control group included 67 patients not treated with magnesium sulphate. Among the patients in the control group, 33% (n= 22) required mechanical ventilation support, compared to only 5% (n= 4) of the patients in the treatment group (p = 0.001). CONCLUSIONS: Intravenous infusion of magnesium sulfate during the first hour of hospitalization in patients with acute severe asthma significantly reduced the percentage of children who required mechanical ventilation support.
Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Magnesium Sulfate/therapeutic use , Acute Disease , Adolescent , Child , Child, Preschool , Disease Progression , Female , Hospitals, University , Humans , Male , Respiration, Artificial , Tertiary Care CentersABSTRACT
Introduction. Magnesium sulfate is a calcium antagonist that inhibits bronchial smooth muscle contraction promoting bronchodilation. It is used for the management of acute severe asthma in children; however most of the studies have been performed in adults. Objective. To evaluate the effectiveness of intravenous magnesium sulfate for the treatment of pediatric patients with acute severe asthma exacerbations. Population and Methods. A clinical, randomized, controlled trial was conducted between March 2006 and March 2011 at Hospital Universitario Austral. Children with acute severe asthma admitted to the emergency department were randomized into two groups. Group A (control group): standard protocol for the initial treatment of acute asthma exacerbation. Group B: treatment protocol with magnesium sulphate for acute severe asthma exacerbation. The primary outcome was the requirement of invasive or non invasive mechanical ventilation support. Results. One hundred and forty three patients randomized into 2 groups were analyzed. The treatment group included 76 patients receiving magnesium sulfate within the first hour of the initiation of rescue treatment at the hospital, and the control group included 67 patients not treated with magnesium sulphate. Among the patients in the control group, 33% (n= 22) required mechanical ventilation support, compared to only 5% (n= 4) of the patients in the treatment group (p = 0.001). Conclusions. Intravenous infusion of magnesium sulfate during the first hour of hospitalization in patients with acute severe asthma significantly reduced the percentage of children who required mechanical ventilation support.
Introducción. El sulfato de magnesio es un antagonista del calcio que inhibe la contracción del músculo liso bronquial y favorece la broncodilatación. Se utiliza en el manejo del asma aguda grave en pediatría no obstante haber sido la mayoría de los estudios desarrollados en adultos. Objetivo. Evaluar la eficacia del sulfato de magnesio endovenoso para exacerbaciones graves de pacientes asmáticos pediátricos. Población y métodos. Se realizó un estudio clínico, controlado y aleatorizado, entre marzo de 2006 y marzo de 2011 en el Hospital Universitario Austral. Los pacientes con asma aguda grave admitidos en Emergencias se aleatorizaron en dos grupos. Grupo A: protocolo inicial estándar de exacerbación asmática aguda grave. Grupo B: protocolo de intervención con sulfato de magnesio de exacerbación asmática aguda grave. La variable principal de resultado fue la necesidad de soporte invasivo o no invasivo ventilatorio mecánico. Resultados. Se analizaron 143 pacientes aleatorizados en 2 grupos. El grupo de intervención de 76 pacientes que recibieron tratamiento con sulfato de magnesio dentro de la primera hora de iniciado el tratamiento de rescate en el hospital, y el grupo control testigo de 67 pacientes que no recibieron tratamiento con sulfato de magnesio. El 33% (n= 22) de los pacientes del grupo control requirió asistencia ventilatoria mecánica, en comparación con solo 4 (5%) de los pacientes del grupo intervención (p= 0,001). Conclusiones. El uso de sulfato de magnesio en infusión endovenosa en la primera hora de ingreso del paciente con asma aguda grave redujo significativamente el porcentaje de niños que requirieron asistencia ventilatoria mecánica.
Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Male , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Magnesium Sulfate/therapeutic use , Acute Disease , Disease Progression , Hospitals, University , Respiration, Artificial , Tertiary Care CentersABSTRACT
Introduction. Magnesium sulfate is a calcium antagonist that inhibits bronchial smooth muscle contraction promoting bronchodilation. It is used for the management of acute severe asthma in children; however most of the studies have been performed in adults. Objective. To evaluate the effectiveness of intravenous magnesium sulfate for the treatment of pediatric patients with acute severe asthma exacerbations. Population and Methods. A clinical, randomized, controlled trial was conducted between March 2006 and March 2011 at Hospital Universitario Austral. Children with acute severe asthma admitted to the emergency department were randomized into two groups. Group A (control group): standard protocol for the initial treatment of acute asthma exacerbation. Group B: treatment protocol with magnesium sulphate for acute severe asthma exacerbation. The primary outcome was the requirement of invasive or non invasive mechanical ventilation support. Results. One hundred and forty three patients randomized into 2 groups were analyzed. The treatment group included 76 patients receiving magnesium sulfate within the first hour of the initiation of rescue treatment at the hospital, and the control group included 67 patients not treated with magnesium sulphate. Among the patients in the control group, 33% (n= 22) required mechanical ventilation support, compared to only 5% (n= 4) of the patients in the treatment group (p = 0.001). Conclusions. Intravenous infusion of magnesium sulfate during the first hour of hospitalization in patients with acute severe asthma significantly reduced the percentage of children who required mechanical ventilation support.(AU)
Introducción. El sulfato de magnesio es un antagonista del calcio que inhibe la contracción del músculo liso bronquial y favorece la broncodilatación. Se utiliza en el manejo del asma aguda grave en pediatría no obstante haber sido la mayoría de los estudios desarrollados en adultos. Objetivo. Evaluar la eficacia del sulfato de magnesio endovenoso para exacerbaciones graves de pacientes asmáticos pediátricos. Población y métodos. Se realizó un estudio clínico, controlado y aleatorizado, entre marzo de 2006 y marzo de 2011 en el Hospital Universitario Austral. Los pacientes con asma aguda grave admitidos en Emergencias se aleatorizaron en dos grupos. Grupo A: protocolo inicial estándar de exacerbación asmática aguda grave. Grupo B: protocolo de intervención con sulfato de magnesio de exacerbación asmática aguda grave. La variable principal de resultado fue la necesidad de soporte invasivo o no invasivo ventilatorio mecánico. Resultados. Se analizaron 143 pacientes aleatorizados en 2 grupos. El grupo de intervención de 76 pacientes que recibieron tratamiento con sulfato de magnesio dentro de la primera hora de iniciado el tratamiento de rescate en el hospital, y el grupo control testigo de 67 pacientes que no recibieron tratamiento con sulfato de magnesio. El 33% (n= 22) de los pacientes del grupo control requirió asistencia ventilatoria mecánica, en comparación con solo 4 (5%) de los pacientes del grupo intervención (p= 0,001). Conclusiones. El uso de sulfato de magnesio en infusión endovenosa en la primera hora de ingreso del paciente con asma aguda grave redujo significativamente el porcentaje de niños que requirieron asistencia ventilatoria mecánica.(AU)
